In this study, we aimed to assess whether mildly decreased eGFR (60–89 ml/min/1.73m2, assessed with CKD-EPI formula) increases the risk of neutropenia during cancer chemotherapy, where primary prophylaxis of FN with G-CSF is not justified. The gene discussed is CSF3; the disease is neutropenia.